Durata Therapeutics, which is developing a Phase 3 antibiotic candidate for acute skin infections, raised $68 million by offering 7.5 million shares at $9, below the range of $11 to $13. Because Durata had planned to offer only 6.3 million shares, the proceeds were just 9% less than expected. Durata Therapeutics plans to list on the NASDAQ under the symbol DRTX. BofA Merrill Lynch and Credit Suisse acted as lead managers on the deal.
